Biodexa Pharmaceuticals (BDRX) to Release Quarterly Earnings on Friday

Biodexa Pharmaceuticals (NASDAQ:BDRX) is projected to issue its Q4 2025 results before the market opens on Friday, April 24th. Analysts expect the company to announce earnings of ($0.0013) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last posted its earnings results on Friday, March 27th. The company reported $3.52 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.53.

Biodexa Pharmaceuticals Trading Down 7.6%

Biodexa Pharmaceuticals stock opened at $4.00 on Wednesday. Biodexa Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $96.50. The stock has a 50-day moving average price of $4.35 and a two-hundred day moving average price of $15.99.

Analysts Set New Price Targets

BDRX has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen cut Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.